Primary end point
angina
Data were available for 99.7% of the 22,823 patient days in the trial. Two participants in the placebo group had missing data. For these participants, the last angina symptom score was carried forward for the primary end point. At 12-week follow-up, the angina symptom score was 2.9 for patients assigned to PCI and 5.6 for patients assigned to placebo (odds ratio, 2.21; 95% confidence interval, 1.41 to 3.47, p<0.001; 